Ram Selva Raju

“Thanks so much for taking my questions, and congratulations on all of the recent progress, progress made on many fronts, I might add. I was wondering if I could ask Deb to perhaps elaborate on the following three aspects as it pertains to the Envisioned Clinical Program.”

“Definitely coming up on exciting times here. I wanted to see if you could elaborate on the updated outlook for Laramestracel in HLHS, specifically as this pertains to the following three items.”

“Firstly, on the commercial side, I was wondering if you could provide us with some additional details regarding the deployment of the field sales force, the degree to which sales reps currently promote more than one product or are dedicated to promoting a single product within your commercial product range, and how…”

“Firstly, I was wondering if you could comment on sort of ongoing evolution of your thinking regarding the positioning of vitacholine, and in particular, how you are thinking about optimizing the value of this franchise, especially given the most recent data that you cited, published in the peer-reviewed journal…”

“Firstly, with respect to El Fabrio, can you maybe give us some insight into additional marketing and promotional initiatives that Chiesi has planned to accelerate the market uptake of this product, specifically in the United States over the course of the remainder of 2026? and also if you can comment on how you expect…”